Lixte Biotechnology Holdings, Inc.
General ticker "LIXT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.3M (TTM average)
Lixte Biotechnology Holdings, Inc. follows the US Stock Market performance with the rate: 31.4%.
Estimated limits based on current volatility of 7.2%: low 5.50$, high 6.35$
Factors to consider:
- Total employees count: 4 (0.0%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Capital shortage, Regulatory and compliance, Market competition, Technology development
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.42$, 6.94$]
- 2026-12-31 to 2027-12-31 estimated range: [1.75$, 5.28$]
Financial Metrics affecting the LIXT estimates:
- Positive: with PPE of -3.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LIXT quotes
Long-term LIXT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $5.09MM | $3.57MM | $5.11MM |
| Operating Income | $-5.09MM | $-3.57MM | $-5.11MM |
| Non-Operating Income | $0.00MM | $-0.01MM | $-0.90MM |
| Interest Expense | $0.02MM | $0.02MM | $0.01MM |
| R&D Expense | $0.90MM | $0.73MM | $0.25MM |
| Income(Loss) | $-5.09MM | $-3.59MM | $-6.01MM |
| Net Income(Loss)* | $-5.09MM | $-3.59MM | $-6.01MM |
| Stockholders Equity | $3.99MM | $0.83MM | $9.66MM |
| Assets | $4.31MM | $1.15MM | $12.73MM |
| Operating Cash Flow | $-4.29MM | $-3.16MM | $-3.07MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $0.00MM | $-3.17MM |
| Financing Cash Flow | $3.14MM | $0.00MM | $10.31MM |
| Earnings Per Share** | $-2.66 | $-1.59 | $-0.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.